Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma
Author:
Affiliation:
1. Royal Marsden Hospital and the Institute of Cancer Research; Sutton UK
2. Hospital Virgen del Rocío; Sevilla Spain
3. Hospital Nuestra Señora de Valme; Sevilla Spain
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12036/fullpdf
Reference23 articles.
1. Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma;Arcaini;Clinical Lymphoma,2004
2. Rituximab monotherapy for splenic marginal zone lymphoma;Bennett;Haematologica,2005
3. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas;Brown;British Journal of Haematology,2009
4. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis;Dungarwalla;British Journal of Haematology,2008
5. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence;Else;Leukemia & Lymphoma,2011
Cited by 69 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study;Haematologica;2024-03-14
2. Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival;Annals of Surgical Oncology;2023-07-30
3. Low‐risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study;British Journal of Haematology;2023-06-30
4. Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly;eJHaem;2023-05-03
5. The role of splenectomy in management of splenic B-cell lymphomas;Leukemia Research;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3